Understanding IgM Structure and Biology to Engineer New Antibody Therapeutics

Area of Science:

• Immunology
• Biochemistry
• Therapeutic Antibody Development

Background:

• Immunoglobulin M (IgM) is a crucial component of adaptive immunity, known for its pentameric/hexameric structure and high avidity binding.
• IgM's ability to activate complement and interact with specific receptors (FcμR, Fcα/μR, pIgR) suggests diverse effector functions and biodistribution.
• Despite decades of interest, no therapeutic IgM antibodies are currently approved, highlighting a gap between potential and clinical application.

Purpose of the Study:

• To review recent advances in IgM biogenesis and structure.
• To discuss the therapeutic advantages of IgM over IgG, including high avidity, target clustering, and receptor interactions.
• To summarize challenges and opportunities in therapeutic IgM production and clinical development.

Main Methods:

• Literature review of recent advances in IgM biology, structure, and function.
• Analysis of preclinical and clinical data comparing IgM and IgG efficacy.
• Examination of IgM production technologies and purification methods.

Main Results:

• IgM exhibits unique structural features (pentamers/hexamers, J-chain) enabling high avidity and efficient complement activation.
• IgM demonstrates superior performance in various in vitro assays compared to IgG.
• Despite preclinical success, IgM antibodies have faced challenges in clinical trials.

Conclusions:

• IgM possesses significant therapeutic potential stemming from its unique biological properties and engineering opportunities.
• Successful clinical translation of IgM therapies requires overcoming challenges in production and a deeper understanding of IgM biology.
• Further research into IgM's complex interactions and optimized production strategies is essential for future therapeutic development.